Visiopharm Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 108

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

Visiopharm General Information

Description

Developer of digital precision pathology software designed to support researchers, diagnostics, drug development and the development of companion diagnostics. The company's software uses artificial intelligence and deep learning to deliver tissue data mining, precision results, standardization of tissue data, and improved productivity, enabling medical practitioners to operate on a wide variety of virtual slide microscopes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • Agern Allé 24
  • 2970 Hoersholm
  • Denmark
+45 88 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Visiopharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 000.00 Completed Generating Revenue
5. Later Stage VC 01-Sep-2020 00.000 000.00 000.00 Completed Generating Revenue
4. Later Stage VC 23-Aug-2018 000.00 000.00 000.00 Completed Generating Revenue
3. Later Stage VC 29-Nov-2016 00.000 00.000 00.00 Completed Generating Revenue
2. Later Stage VC 30-Apr-2015 $868K $1.87M 00.00 Completed Startup
1. Later Stage VC 05-Oct-2007 $997K $997K 00.000 Completed Generating Revenue
To view Visiopharm’s complete valuation and funding history, request access »

Visiopharm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 000.00 000.00 00 000.00 00.000
Ordinary 000,000 000.00 000.00 00 000.00 00.000
Ordinary 000,000 000.0 000.0 00 000.0 0.000
Ordinary 00,000 000.00 000.00 00 000.00 0.00
B Shares 00,000 00.00 00.00 00 00.00 0.00
A Shares 97,176 $8.67 $8.67 1x $8.67 5.98%
Ordinary 5,000 $0.64 $0.64 1x $0.64 0.31%
To view Visiopharm’s complete cap table history, request access »

Visiopharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of digital precision pathology software designed to support researchers, diagnostics, drug development and the
Decision/Risk Analysis
Hoersholm, Denmark
108 As of 2023
000.00
00000 00000 000.00

000000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugia
00000 0000000000 000
Albuquerque, NM
000 As of 0000
000000000

000000

is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000000000000 000000
Helsinki, Finland
00 As of 0000
000.00
00000 0000-00-00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Visiopharm Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Indica Labs Venture Capital-Backed Albuquerque, NM 000 000000000
Aiforia Formerly VC-backed Helsinki, Finland 00 000.00 00000000 000.00
Ibex Medical Analytics Venture Capital-Backed Tel Aviv, Israel 00 00000 000000000000 00000
Orchard Software Private Equity-Backed Carmel, IN 000 000000000000
Epic (Healthcare Technology Systems) Formerly PE-Backed Verona, WI 00000 0000 00000000000 0000
You’re viewing 5 of 10 competitors. Get the full list »

Visiopharm Patents

Visiopharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230122073-A1 Medical image analysis system and method for managing medical images Pending 05-Mar-2020 0000000000
EP-4115387-A1 Medical image analysis system and method for managing medical images Pending 05-Mar-2020 0000000000
US-20220260825-A1 Scanning/pre-scanning quality control of slides Pending 28-Jun-2019 0000000000
EP-3757872-A1 Scanning/pre-scanning quality control of slides Inactive 28-Jun-2019 0000000000 0
EP-3991088-A1 Scanning/pre-scanning quality control of slides Pending 28-Jun-2019 G06T7/0012
To view Visiopharm’s complete patent history, request access »

Visiopharm Executive Team (13)

Name Title Board Seat Contact Info
Michael Grunkin Ph.D Co-Founder, Chief Executive Officer & Managing Director
Kristian Dalhof Nielsen Chief Financial Officer
Christian Kaltoft Chief Operating Officer
Johan Hansen Co-Founder, Chief Technical Officer & Vice President of Chief Technology Officer
Amanda Lowe Managing Director, Americas
You’re viewing 5 of 13 executive team members. Get the full list »

Visiopharm Board Members (8)

Name Representing Role Since
Claus Møller MD The ATP Group Board Member 000 0000
Jeannett Hvidkjær Visiopharm Board Member 000 0000
Martin Bonde Ph.D Self Board Member 000 0000
Morten Frost Visiopharm Board Member 000 0000
Patrik Dahlen Ph.D Self Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Visiopharm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Visiopharm Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BankInvest Group Asset Manager Minority 000 0000 000000 0
C. L. David Foundation and Collection Limited Partner Minority 000 0000 000000 0
Denmark's Export and Investment Fund Venture Capital Minority 000 0000 000000 0
The ATP Group Limited Partner Minority 000 0000 000000 0
The Growth Fund PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Visiopharm Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
LRI Imaging 01-Dec-2016 0000000000 Other Devices and Supplies 0000000 0
Digital Pathology Consultants 08-Dec-2012 Merger/Acquisition Consulting Services (B2B) 0000000 0
To view Visiopharm’s complete acquisitions history, request access »

Visiopharm Subsidiaries (1)

Company Name Industry Location Founded
LRI Imaging Other Devices and Supplies Lund, Sweden 0000
To view Visiopharm’s complete subsidiaries history, request access »

Visiopharm FAQs

  • When was Visiopharm founded?

    Visiopharm was founded in 2002.

  • Who is the founder of Visiopharm?

    Michael Grunkin Ph.D and Johan Hansen are the founders of Visiopharm.

  • Who is the CEO of Visiopharm?

    Michael Grunkin Ph.D is the CEO of Visiopharm.

  • Where is Visiopharm headquartered?

    Visiopharm is headquartered in Hoersholm, Denmark.

  • What is the size of Visiopharm?

    Visiopharm has 108 total employees.

  • What industry is Visiopharm in?

    Visiopharm’s primary industry is Decision/Risk Analysis.

  • Is Visiopharm a private or public company?

    Visiopharm is a Private company.

  • What is Visiopharm’s current revenue?

    The current revenue for Visiopharm is 000000.

  • How much funding has Visiopharm raised over time?

    Visiopharm has raised $26.4M.

  • Who are Visiopharm’s investors?

    BankInvest Group, C. L. David Foundation and Collection, Denmark's Export and Investment Fund, The ATP Group, and The Growth Fund are 5 of 6 investors who have invested in Visiopharm.

  • Who are Visiopharm’s competitors?

    Indica Labs, Aiforia, Ibex Medical Analytics, Orchard Software, and Epic (Healthcare Technology Systems) are some of the 10 competitors of Visiopharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »